Trends in the Prescribing of Psychotropic Medications to Preschoolers | Adolescent Medicine | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.234.102. Please contact the publisher to request reinstatement.
1.
Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s.  Pediatrics.1996;98(6 pt 1):1084-1088.Google Scholar
2.
Zito JM, dosReis S, Safer DJ, Gardner J. Trends in psychotropic prescriptions for youths with Medicaid insurance from a midwestern state: 1987-1995. Paper presented at: New Clinical Drug Evaluation Unit Meeting; June 1998; Boca Raton, Fla.
3.
Greenhill LL. The use of psychotropic medication in preschoolers: indications, safety, and efficacy.  Can J Psychiatry.1998;43:576-581.Google Scholar
4.
Minde K. The use of psychotropic medication in preschoolers: some recent developments.  Can J Psychiatry.1998;43:571-575.Google Scholar
5.
Rappley MD, Gardiner JC, Mullan PB, Wang J, Alvarez FJ. Psychotropic medications in children ages 1 to 3 with ADHD. Paper presented at: Pediatric Academic Societies Meeting (Joint Specialties and Themes: Behavioral Pediatrics); May 4, 1998; New Orleans, La.
6.
Pathiyal A, Miwa LJ, Sverdiov LS, Gardner E, Jones JK. Patterns of methylphenidate use. Paper presented at: American Society for Clinical Pharmacology and Therapeutics; March 31, 1998; New Orleans, La.
7.
Vitiello B, Jensen PS. Medication development and testing in children and adolescents: current problems, future directions.  Arch Gen Psychiatry.1997;54:871-876.Google Scholar
8.
Grinfeld MJ. Psychoactive medications and kids: new initiatives launched.  Psychiatric Times.1998;15:69.Google Scholar
9.
Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, Fox M. Prevalence variations in psychotropic treatment of children.  J Child Adolesc Psychopharmacol.1998;8:99-105.Google Scholar
10.
Jensen PS, Vitiello B, Leonard H, Laughren TP. Child and adolescent psychopharmacology: expanding the research base.  Psychopharmacol Bull.1994;30:3-8.Google Scholar
11.
Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.  J Child Adolesc Psychopharmacol.1998;8:13-25.Google Scholar
12.
Valentine J, Zubrick S, Sly P. National trends in the use of stimulant medication for attention deficit hyperactivity disorder.  J Paediatr Child Health.1996;32:223-227.Google Scholar
13.
Safer DJ, Zito JM. Pharmacoepidemiology of methylphenidate and other stimulants for the treatment of ADHD. In: Greenhill LL, Osman BB, eds. Ritalin: Theory and Practice. 2nd ed. Larchmont, NY: MA Liebert Publishers; 2000:7-26.
14.
Davilla RR, Williams ML, MacDonald JT. Clarification of policy to address the needs of children with attention deficit hyperactivity disorders within general and/or special education. Memorandum from: US Dept of Education. Washington, DC: US Dept of Education, Office of Special Education; September 16, 1991.
15.
Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine.  J Am Acad Child Adolesc Psychiatry.1997;36:539-544.Google Scholar
16.
Swanson JM, Flockhart DA, Udrea D, Cantwell DP, Connor DF, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy [letter].  J Child Adolesc Psychopharmacol.1995;5:301-304.Google Scholar
17.
Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases.  J Am Acad Child Adolesc Psychiatry.1996;35:599-605.Google Scholar
18.
Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of Ritalin side effects.  Pediatrics.1993;91:1101-1106.Google Scholar
19.
Erickson SJ, Duncan A. Clonidine poisoning—an emerging problem: epidemiology, clinical features, management and preventive strategies.  J Paediatr Child Health.1998;34:280-282.Google Scholar
20.
Kappagoda C, Schell DN, Hanson RM, Hutchins P. Clonidine overdose in childhood: implications of increased prescribing.  J Paediatr Child Health.1998;34:508-512.Google Scholar
21.
Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death.  J Child Adolesc Psychopharmacol.1995;5:157-166.Google Scholar
22.
Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate and clonidine: a clinically sound medication option vs. ill-advised.  J Am Acad Child Adolesc Psychiatry.1999;38:614-619.Google Scholar
23.
Pincus HA, Tanielian TL, Marcus SC.  et al.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.  JAMA.1998;279:526-531.Google Scholar
24.
Foxman B, Valdez RB, Brook RH. Childhood enuresis: prevalence, perceived impact, and prescribed treatments.  Pediatrics.1986;77:482-487.Google Scholar
25.
Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents.  J Am Acad Child Adolesc Psychiatry.1999;38:513-516.Google Scholar
26.
Traversa G, Spila-Alegiani S, Arpino C, Ferrara M. Prescription of neuroleptics for children and adults in Italy.  J Child Adolesc Psychopharmacol.1998;8:175-180.Google Scholar
27.
Perrin JM, Kuhlthau K, McLaughlin TJ, Ettner SL, Gortmaker SL. Changing patterns of conditions among children receiving Supplemental Security Income disability benefits.  Arch Pediatr Adolesc Med.1999;153:80-84.Google Scholar
28.
Hoagwood K, Jensen PS, Petti T, Burns BJ. Outcomes of mental health care for children and adolescents, I: a comprehensive conceptual model.  J Am Acad Child Adolesc Psychiatry.1996;35:1055-1063.Google Scholar
29.
Vitiello B. Pediatric psychopharmacology and the interaction between drugs and the developing brain.  Can J Psychiatry.1998;43:582-584.Google Scholar
Original Contribution
February 23, 2000

Trends in the Prescribing of Psychotropic Medications to Preschoolers

Author Affiliations

Author Affiliations: School of Pharmacy (Drs Zito, dosReis, and Mr Gardner) and School of Medicine (Dr Zito), University of Maryland, and School of Medicine, Johns Hopkins University (Dr Safer), Baltimore, Md; and Center for Health Research, Kaiser Permanente, Portland, Ore (Drs Boles and Lynch).

JAMA. 2000;283(8):1025-1030. doi:10.1001/jama.283.8.1025
Abstract

Context Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates.

Objectives To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span.

Design Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995).

Setting and Participants From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146,369 to 158,060; in a mid-Atlantic state Medicaid (MAM) program, from 34,842 to 54,237; and in an HMO setting in the Northwest, from 19,107 to 19,322.

Main Outcome Measures Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites.

Results The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2 through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents.

Conclusions In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.

×